Your browser doesn't support javascript.
loading
Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate.
Carrez, Romain; Brillault, Julien; Grégoire, Nicolas; Lamarche, Isabelle; Laroche, Julian; Couet, William; Marchand, Sandrine.
Afiliação
  • Carrez R; INSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
  • Brillault J; Université de Poitiers, UFR Médecine-Pharmacie, Poitiers, France.
  • Grégoire N; INSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
  • Lamarche I; Université de Poitiers, UFR Médecine-Pharmacie, Poitiers, France.
  • Laroche J; INSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
  • Couet W; Université de Poitiers, UFR Médecine-Pharmacie, Poitiers, France.
  • Marchand S; INSERM, U1070, UFR de Médecine Pharmacie, Université de Poitiers, TSA 51106, Poitiers, France.
Article em En | MEDLINE | ID: mdl-30962337
ABSTRACT
The aim of this study was to investigate the pharmacokinetics of oseltamivir phosphate, a prodrug, and its active moiety in plasma and lung after its nebulization and intravenous administration in rats. Only 2% of prodrug was converted into active moiety presystematically, attesting to a low advantage of oseltamivir phosphate nebulization, suggesting that oseltamivir phosphate nebulization is not a good option to obtain a high exposure of the active moiety at the infection site within lung.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Fármacos / Oseltamivir Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Fármacos / Oseltamivir Idioma: En Ano de publicação: 2019 Tipo de documento: Article